1. Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate);Abe;ACS Med. Chem. Lett.,2011
2. Antitumor Activities of JTP-74057 (GSK1120212), a Novel MEK1/2 Inhibitor, on Colorectal Cancer Cell Lines In Vitro and In Vivo;Yamaguchi;Int. J. Oncol.,2011
3. GSK1120212 (JTP-74057) is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition;Gilmartin;Clin. Cancer Res.,2011
4. Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma;Flaherty;N. Engl. J. Med.,2012
5. http://www.gsk.com/en-gb/media/press-releases/2013/two-new-gsk-oral-oncology-treatments-braf-inhibitor-tafinlar-dabrafenib-capsules-and-the-first-mek-inhibitor-mekinist-trametinib-tablets-approved-by-fda-as-single-agent-therapies/.